Memorial Sloan Kettering Cancer Center

Eureka Therapeutics, Inc.

Andres Lopez-Albaitero

Nai-Kong V Cheung

Hong Xu

Cheng Liu

Hong Liu

Su Yan

Mahiuddin Ahmed

Jingyi Xiang

Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.

Bispecific HER2 and CD3 binding molecules

Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.

T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA

Growing community of inventors

New York, NY, United States of America

Andres Lopez-Albaitero